Clinical Scorecard: Estriol may ease menopause-related cognitive decline
At a Glance
| Category | Detail |
|---|---|
| Condition | Menopause-related cognitive decline |
| Key Mechanisms | Estriol treatment may improve cognitive function via estrogen receptor beta signaling in brain cells. |
| Target Population | Menopausal women experiencing cognitive decline. |
| Care Setting | Standard patient care in a clinical setting. |
Key Highlights
- 20 menopausal women with cognitive decline participated in the study.
- Participants received oral estriol daily for 12 months.
- Significant improvements were observed in cognitive symptoms across all assessed domains.
- No randomization or placebo group was included in the study.
- Cognitive changes were self-reported rather than measured through objective testing.
Guideline-Based Recommendations
Diagnosis
- Cognitive symptoms assessed using the Voskuhl Menopause Brain Fog Assessment.
Management
- Consider estriol-based hormone treatment for menopausal women with cognitive decline.
Monitoring & Follow-up
- Monitor cognitive symptoms and overall health during treatment.
Risks
- Caution advised due to lack of randomization and small sample size.
Patient & Prescribing Data
Menopausal women aged around 53.5 years.
Estriol doses varied (2 mg, 4 mg, 8 mg) and were individualized.
Clinical Best Practices
- Evaluate cognitive symptoms in menopausal women.
- Consider individualized hormone therapy based on clinical need.
- Encourage further research into estriol's effects on cognition.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
